Prognostic and clinical significance of long non-coding RNA HNF1A-AS1 in solid cancers
A systematic review and meta-analysis

Xi Zhou, MDa, Yang-Hua Fan, MDb, Yan Wang, MDC, Yong Liu, MDa,∗

Abstract
Background: LncRNA HNF1A Antisense RNA 1 (HNF1A-AS1) is often dysregulated in cancer. We performed this meta-analysis to clarify the usefulness of HNF1A-AS1 as a prognostic marker in malignant tumors.

Methods: The PubMed, OVID, and Web of Science databases were searched from inception to January 11, 2018. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between HNF1A-AS1 expression and survival. Odds ratios (ORs) were calculated to assess the association between HNF1A-AS1 expression and pathological parameters.

Results: Eight studies with a total of 802 patients were included in the study. The pooled hazard ratio (HR) suggested high HNF1A-AS1 expression correlated with poor overall survival (OS) (HR = 4.85, 95% CI 1.27–17.79), distant metastasis (DFS) (HR = 6.87, 95% CI 2.04–23.40), and disease-free survival (DFS) (HR = 6.73, 95% CI 1.13–31.64) in cancer patients. High HNF1A-AS1 expression also correlated with poor histological grade (OR = 1.88, 95% CI 1.27–2.79), high tumor stage (OR = 4.04, 95% CI 2.53–6.47), lymph node metastasis (LNM) (OR = 4.53, 95% CI 2.30–8.92), and distant metastasis (OR = 6.99, 95% CI 2.88–15.16). Begg funnel plot did not show any evidence of obvious asymmetry for high tumor stage (P < 0.05) and LNM (P > 0.05).

Conclusions: Thus high HNF1A-AS1 expression is predictive of poor OS, DFS, lymph node metastasis, distant metastasis, histological grade, and larger tumor stage, which suggests high HNF1A-AS1 expression may serve as a novel biomarker of poor prognosis in cancer.

Abbreviations: BC = bladder cancer, CRC = colorectal cancer, DM = distant metastasis, GAPDH = glyceraldehyde-3-phosphate dehydrogenase, HNF1A-AS1 = HNF1A Antisense RNA 1, HR = hazard ratio, HTS = high tumor stage, LADC = lung adenocarcinoma, LNM = lymph node metastasis, LTS = lager tumor size, NSCLC = non-small cell lung cancer, OS = overall survival, OSC = osteosarcoma, PHG = poor histological grade.

Keywords: HNF1A-AS1, lncRNA, metastasis, neoplasms, prognosis

1. Introduction
It was recently reported that approximately 1.7 million new cancer cases and 600 thousand cancer deaths are projected to occur in the U.S. in 2017.[1] However, the 5-year survival rate of most cancers remains still low, and many scientists are looking for new biomarkers useful for diagnosis or determining prognosis in cancer.

Long noncoding RNA (lncRNA) is defined as transcribed RNA molecules greater than 200 nucleotides in length that is lack a meaningful open reading frame.[2] LncRNA has many important functions in disease, including epigenetic regulation, transcriptional and posttranscriptional regulation.[3] Moreover, it now appears that lncRNA dysregulation may be involved in various types of cancer.[4–7] For example, some lncRNAs play a key role in cancer cell proliferation, invasion, and metastasis,[8–9] suggesting lncRNA may be a useful marker of cancer prognosis.[10]

The lncRNA HNF1A Antisense RNA 1 (HNF1A-AS1) is transcribed as a 2.455kb lncRNA in the opposite direction of HNF1A gene transcription. HNF1A-AS is a bidirectional lncRNA located on chromosome 12.[11] In addition, HNF1A-AS1 is reportedly associated with various tumor biological parameters,[12–14] including overall survival (OS), lymph node
metastasis, and tumor stage. But although HNF1A-AS1 expression may affect prognosis and metastasis of human cancers, most studies reported so far are limited by discrete outcomes and sample size. We therefore performed this update meta-analysis to determine the prognostic value of HNF1A-AS1 in cancer patients.

2. Materials and methods

2.1. Literature collection

According to the standard guidelines of meta-analyses, a systematic search was performed by 2 authors independently in the electronic databases of Pubmed, OVID, and Web of Science for relevant articles that concerned HNF1A-AS1 as a prognostic biomarker for the survival of cancer patients. The latest search was updated on January 11, 2018. We performed literature search by both text word and MeSH strategy with the terms “HNF1A-AS1”, “HNF1A Antisense RNA 1”, “lncRNA HNF1A AS1”, “lncRNA or “non-coding RNA” or “long intergenic noncoding RNA”, “carcinoma” or “neoplasm” or “tumor” or “cancer”, “prognostic” or “prognosis”, “outcome” or “survival” or “recurrence”. The strategy was correspondingly adjusted in the different databases. In the retrieval process, we made a manual search using the reference lists of the relevant articles to include eligible studies. All the analyses were conducted on the basis of the prior published researches. Therefore, it did not require patient consent or ethical approval.

2.2. Study selection

Two researchers evaluated all of the included studies and extracted the data independently. The inclusion criteria were as follows:

1. the relationship between HNF1A-AS1 expression and survival was measured in multiple human tumors;
2. the expression levels of HNF1A-AS1 in human tumor tissue were measured, and the patients were grouped according to the expression levels of HNF1A-AS1;
3. all of the tumors were confirmed by pathological or histological examinations;
4. studies statistically analyzed patient survival or pathological parameters such as lymph node metastasis, tumor size, and tumor stage, with respect to HNF1A-AS1 expression.

The following studies were excluded:

1. reviews, letters, editorials, and expert opinions;
2. non-English language and non-human studies;
3. studies with the molecular structure and functions of HNF1A-AS1 only;
4. database analysis without original data.

2.3. Data extraction

Two reviewers extracted and examined the data from the original articles independently. Disagreements in the literature assessment were resolved through consensus with a third reviewer. The following data were collected: surname of the first author, publication year, country, tumor type, sample size, the number of patients with larger tumor size, poor histological (differentiation) grade, high tumor stage, lymph node metastasis and distant metastasis, reference gene, HR and 95% CI of elevated HNF1A-AS1 for OS.

2.4. Statistical methods

Statistical analyses were performed using Stata version 12.0 software (StataCorp LLC, College Station, Texas, USA). The heterogeneity among different studies was measured by the Q and I² tests. A probability value of $I^2 \geq 50\%$ and $P < .1$ indicated the existence of significant heterogeneity. A random effects model or fixed effects model was used depending on the results of heterogeneity analysis. If there was a significant heterogeneity among the studies, the random-effects model was adopted, and the fixed-effects model was used if there was no obvious heterogeneity.

Pooled HRs and ORs were extracted from the published data. If the HRs can be obtained directly from the publication, we used crude ones. While the HR and 95% CI were not directly reported in the studies, survival information was extracted from Kaplan–Meier curves and was used to estimate the HR. The log HR and SE were used to summarize the outcome of survival. An observed HR of $>1$ indicated poor prognosis in patients with high HNF1A-AS1 expression. OR and their 95% CI were combined to assess the association between HNF1A-AS1 expression and clinicopathological parameters, including tumor size, histological grade (differentiation), tumor stage, lymph node metastasis, and distant metastasis. The sensitivity analysis was also performed to assess the stability of the results. The potential publication bias was assessed by the Begg funnel plot and Egger test. $P < .05$ was considered statistically significant.

3. Results

3.1. Studies characteristics

The detailed screening process is shown in detail in Figure 1. According to the inclusion and exclusion criteria, 8 studies and 802 patients were included in the meta-analysis. Additionally, the characteristics of the 8 studies included in the present meta-analysis are summarized in Table 1. The subject number of 8 studies ranged from 40 to 177, with a mean sample size of 100.25. All studies were conducted in China and were published between 2015 and 2017. Among the 8 studies, 3 focused on colorectal cancer (CRC)[20,21,25] 2 focused on osteosarcoma (OSC)[19,26] and 1 each on non-small cell lung cancer (NSCLC),[22] lung adenocarcinoma (LADC),[23] bladder cancer (BC).[24] All of the clinicopathological parameters were all dependent on the pathology. The reference gene of lncRNA HNF1A-AS1 in these studies were found to be inconsistent, including GAPDH,[19,21-23,26] β-actin,[20,24,25] GAPDH, and 18S.[26]

3.2. Association between the HNF1A-AS1 expression level and survival

We performed a cumulative meta-analysis to assess the function of HNF1A-AS1 for overall survival (OS) in patients with cancer. Additionally, 6 included studies with 683 patients reported the relationship between OS and HNF1A-AS1. The random effects model was used for significant heterogeneity ($I^2 = 79.5\%$, $P_{(I^2)} < .000$). A significant association was observed between HNF1A-AS1 and OS in cancer patients (pooled HR $= 4.85$, 95% CI: 2.43–9.68; Fig. 2).
Table 1

The basic information and data of all included studies in the meta-analysis.

| Study | Year | Region | Tumor type | Sample size | Total | LTS | PHG | HTS | LNM | DM | Total | LTS | PHG | HTS | LNM | DM | Reference gene | HR(95% CI) |
|-------|------|--------|------------|--------------|-------|-----|-----|-----|-----|-----|-------|-----|-----|-----|-----|-----|----------------|------------|
| Cai   | 2016 | China  | OSC        | 72           | 36    | 20  | –   | 23  | –   | –   | 36   | 18  | –   | 17  | –   | –   | GAPDH         | 2.634(1.550–5.647) |
| Fang  | 2017 | China  | CRC        | 98           | 49    | 21  | 13  | 37  | 37  | 12  | 49   | 26  | 9   | 22  | 20  | 3   | β-actin       | 25.918(9.529–70.498) |
| Gong  | 2017 | China  | CRC        | 151          | 76    | 34  | 20  | 57  | 57  | 24  | 75   | 17  | 8   | 17  | 17  | 5   | GAPDH         | 12.247(5.171–29.008) |
| Ma    | 2016 | China  | NSCLC      | 177          | 87    | –   | 27  | 51  | 52  | –   | 90   | –   | 20  | 32  | 35  | –   | GAPDH         | 3.166(1.451–5.332)  |
| Wu    | 2015 | China  | LADC       | 40           | 25    | 16  | 8   | 18  | 17  | –   | 15   | 4   | 7   | 6   | 4   | –   | GAPDH         | –           |
| Zhai  | 2017 | China  | BC         | 79           | 51    | 34  | 34  | 40  | 4   | –   | 28   | 13  | 10  | 15  | 1   | –   | β-actin       | –           |
| Zhang | 2015 | China  | CRC        | 142          | 71    | –   | –   | –   | –   | –   | 71   | –   | –   | –   | –   | –   | β-actin       | 2.57(1.27–5.32)   |
| Zhao  | 2016 | China  | OSC        | 43           | 22    | 15  | –   | 17  | –   | 9   | 21   | 12  | –   | 7   | –   | 2   | GAPDH         | 2.637(1.391–7.417) |

The dashes represent no data.

BC = bladder cancer, CRC = colorectal cancer, DM = distant metastasis, HR = hazard ratio, HTS = high tumor stage, LADC = lung adenocarcinoma, LNM = lymph node metastasis, LTS = larger tumor size, NSCLC = non-small cell lung cancer, OS = overall survival, OSC = osteosarcoma, PHG = poor histological grade.

Figure 1. Flowchart presented the steps of study selection in this meta-analysis.
We performed cumulative meta-analysis to determine the role of HNF1A-AS1 in disease-free survival (DFS) of 240 cancer patients\textsuperscript{[20,25]} from the eligible studies (Fig. 2). Statistical analyses revealed that HNF1A-AS1 was associated with DFS (pooled HR = 6.34, 95% CI: 1.03–39.12) of cancer patients. The random effects model was adopted because of the significant heterogeneity between studies.

This result demonstrated that a high expression of HNF1A-AS1 might be correlated with a shorter OS and DFS in cancer patients. Thus, we found that HNF1A-AS1 was an independent factor of survival among patients with cancer.

### 3.3. Association between the HNF1A-AS1 expression level and tumor size

The correlations between HNF1A-AS1 expression and tumor size are presented in Figure 3. Six studies with 483 patients declared the association between the HNF1A-AS1 expression levels and number of cancer patients with larger tumor size. There was significant heterogeneity in these studies, and the random-effects model was used ($I^2 = 50.9\%$, $P_Q = 0.070$). The analysis showed a pooled OR = 1.74 (95% CI: 1.00–3.04; high vs low HNF1A-AS1 expression; Fig. 3). In a sensitivity analysis of all included studies, heterogeneity disappeared after the Cai et al study\textsuperscript{[19]} were excluded ($I^2 = 0\%$, $P_Q = .51$), and the odds ratio (OR), expressed as high HNF1A-AS1 expression group vs low HNF1A-AS1 expression group, was 2.23 (95% CI: 1.46–3.41).

According to the result, there was not a significant difference in the larger tumor size incidence between the 2 groups, additional more studies will be needed to confirm the relationship between HNF1A-AS1 and histological grade in cancer patients.

### 3.4. Association between the HNF1A-AS1 expression level and histological grade

A total of 545 patients with cancer from 5 eligible studies were collected and analyzed. The fixed effects model was used for limited heterogeneity ($I^2 = 39.5\%$, $P_Q = .188$). The odds ratio (OR), expressed as high HNF1A-AS1 expression group vs low HNF1A-AS1 expression group, was 1.88 (95% CI: 1.27–2.79, Fig. 4). According to the result, there was a significant difference in the poor histological (differentiation) grade incidence between the 2 groups. And the results demonstrated that high expression of HNF1A-AS1 significantly predicted more prone to poor differentiation grade for patients with cancer.

### 3.5. Association between the HNF1A-AS1 expression level and tumor stage

Six hundred sixty patients in 7 eligible studies were included to detect the relationship between the HNF1A-AS1 expression levels and tumor stage in this meta-analysis. The random effects model was used for significant heterogeneity ($I^2 = 44.6\%$, $P_Q = .094$). A significant connection was found between a high HNF1A-AS1 expression level and high tumor stage in cancer patients (pooled OR = 4.04, 95% CI: 2.53–6.47, Fig. 5).

From the analysis results, the tumor stage was significantly increased in the high HNF1A-AS1 expression group compared with that in the low HNF1A-AS1 expression group, and the results demonstrated that a high expression of HNF1A-AS1 significantly increased the risk of high tumor stage.
3.6. Association between the HNF1A-AS1 expression level and lymph node metastasis

A total of 545 patients with cancer from 5 eligible studies were collected and analyzed. The random effects model was used for significant heterogeneity ($I^2 = 58.2\%$, $P_Q = .048$). The odds ratio (OR), expressed as high HNF1A-AS1 expression group vs low HNF1A-AS1 expression group, was 4.53 (95% CI: 2.30–8.92, Fig. 6). According to the result, there was a significant difference in the lymph node metastasis incidence between the 2 groups. And the results demonstrated that high expression of HNF1A-AS1 significantly predicted more prone to developing lymph node metastasis for patients with cancer.

Figure 3. Forest plot showed the association between tumor size and HNF1A-AS1 expression level in cancer.

Figure 4. Forest plot of studies evaluated the correlation between histological grade and HNF1A-AS1 expression level in cancer.
3.7. Association between the HNF1A-AS1 expression level and distant metastasis

Two hundred ninety two patients with cancer from 3 eligible studies were collected and analyzed. The fix effects model was used for limited heterogeneity ($I^2 = 0.0\%, P_{Q} = .948$). The odds ratio (OR), expressed as the high HNF1A-AS1 expression group vs low HNF1A-AS1 expression group was 5.99 (95% CI: 2.88–12.48, Fig. 7). According to the result, there was a significant difference between the 2 groups in the distant metastasis incidence. Additionally, the results demonstrated that a high
expression of HNF1A-AS1 significantly predicted a higher tendency to develop distant metastasis in patients with cancer.

3.8. Publication bias

Next, a Begg funnel plot was conducted to evaluate publication bias. The figure of the Begg funnel plot (Fig. 8) did not show any evidence of obvious asymmetry for high tumor stage (Pr > |z| = 0.368). Similarly, there were no evidences for significant publication bias in terms of LNM (Pr > |z| = 1.000, Fig. 9).

4. Discussion

Cancer remains a serious threat to human health, and the incidence of cancer has increased gradually in recent years. The occurrence of metastasis is an important indicator of a poor prognosis, but the precise mechanism on metastasis remains uncertain in cancer patients. At present, cancer research hotspot-molecular biomarkers play a critical role in the prediction and treatment of cancer. It therefore continues to be necessary to identify new molecular markers predictive of tumor metastasis.
Among these molecular markers are lncRNAs, which can impact both the occurrence and development of tumors, and have shown potential to serve as easily collected biomarkers useful for diagnosing and monitoring tumors.[31]

Previous studies have shown that HNF1A-AS1 is a critical oncogene in a variety of human cancer types, including osteosarcoma, colorectal cancer, non-small cell lung cancer, bladder cancer, and lung adenocarcinoma.[19-26] Recent advances have confirmed that HNF1A-AS1 is associated with poor survival in osteosarcoma patients, and increased expression of HNF1A-AS1 was observed in local recurrences compared with paired primary osteosarcoma.[19] And Fang et al demonstrated that patients with high HNF1A-AS1 expression had an increased risk of tumor recurrence and shorter survival.[20] In addition, Zhan et al[24] found that HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. And Zhang et al[32] reported that HNF1A-AS1 promotes proliferation and invasion via regulating miR-17-5p in non-small cell lung cancer. These studies suggest that lncRNA HNF1A-AS1 may serve as an important prognostic factor in cancer patients. Until now, the underlying mechanisms by which HNF1A-AS1 affected human cancers and its utility as a biomarker remained largely unclear. Through this meta-analysis, we explored the clinicopathologic significance and prognostic value of HNF1A-AS1 in cancer patients.

A total of 802 patients with cancer from 8 eligible studies were collected and analyzed in this study. A random effects model or fixed effects model was used depending on the results of heterogeneity analysis. We found that high HNF1A-AS1 expression may indicate a poor prognosis in cancer patients. By combining HRs from Cox multivariate analyses, we detected a significant difference in OS between high and low HNF1A-AS1 expression groups. We found that high HNF1A-AS1 expression was significantly associated with DFS in different types of cancer. Furthermore, high HNF1A-AS1 expression correlated significantly with high tumor stage, poor histological grade, lymph node metastasis, and distant metastasis in cancer patients. Taken together, these findings suggest HNF1A-AS1 may be a useful prognostic biomarker of poor outcome in most cancers.

5. Limitations
There were several limitations that must be taken into account while interpreting the conclusions of the present meta-analysis. First, all included studies were from China. Therefore our data may not be globally applicable. Second, the included types and numbers of cancers were small. Third, 4 articles did not mention the criterion used to define high expression, and the cut-off value for high expression in the remaining 4 articles was the median. Third, since there is no literature to study the role of HNF1A-AS1 in non-solid tumors, we mainly studied the effect of HNF1A-AS1 expression level on solid tumors. Therefore, additional well-designed, high-quality studies are needed to confirm the function of HNF1A-AS1 in cancer.

6. Conclusion
In sum, high levels of HNF1A-AS1 expression in multiple cancers is significantly correlated with poor OS, DFS, lymph node metastasis, distant metastasis, histological grade, larger tumor stage. Therefore, HNF1A-AS1 expression may serve as a promising biomarker for predicting prognosis and metastasis in cancer patients.

Author contributions
Data curation: Xi Zhou, Yang-Hua Fan, Yan Wang.
Funding acquisition: Xi Zhou.
Investigation: Xi Zhou, Yang-Hua Fan, Yan Wang, Yong Liu.
Methodology: Yang-Hua Fan.
Supervision: Yong Liu.
Validation: Xi Zhou.
References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
[2] Johnsson P, Lipovich L, Grander D, et al. Evolutionary conservation of long non-coding RNAs: sequence, structure, function. Biochim Biophys Acta 2014;1840:1063–71.
[3] Fan YH, Fang H, Ji CX, et al. Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: a meta-analysis. Clin Chim Acta 2017;466:120–6.
[4] Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget 2016;7:30523–33.
[5] Cheng N, Li X, Zhao C, et al. Microarray expression profile of long noncoding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015;33:833–9.
[6] Huang NS, Chi YY, Xue JY, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget 2016;7:37957–65.
[7] Zhou Y, Wang DL, Pang Q. Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma. Eur Rev Med Pharmacol Sci 2016;20:3035–9.
[8] Guo H, Hu G, Yang Q, et al. Knockdown of long non-coding RNA CCAT2 suppressed proliferation and migration of glioma cells. Oncotarget 2016;7:81806–14.
[9] Miao L, Huang Z, Zengli Z, et al. Loss of long noncoding RNA FOXF1-2016;8:3503–12.
[10] Liu Z, Wei X, Zhang A, et al. Long non-coding RNA HNF1A-AS1 functioned as an oncogene and autophagy promoter in hepatocellular carcinoma through sponging hsa-miR-30b-5p. Biochem Biophys Res Commun 2016;473:1268–75.
[11] Wang G, Zhao W, Gao X, et al. HNFA1-AS1 promotes growth and metastasis of esophageal squamous cell carcinoma by sponging miR-214 to upregulate the expression of SOX-4. Int J Oncol 2017;51: 637–67.
[12] Wang G, Mou L, Chai HX, et al. Long non-coding RNA HNFA1-AS1 promotes hepatocellular carcinoma cell proliferation by repressing NDK1 and P21 expression. Biomed Pharmacother 2017;89:926–32.
[13] McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.
[14] Altman DG, McShane LM, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012;9:e1001216.
[15] Fan YH, Xie L, Ye MH, et al. Long noncoding RNA UCA1 can serve as a prognostic marker in human cancer: a meta-analysis. Int J Clin Exp Med 2017;10:357–66.
[16] Sun DW, Zhang YY, Sun XD, et al. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta 2015;448: 161–9.
[17] Cai L, Lv J, Zhang Y, et al. The IncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma. J Cell Mol Med 2017;21:2654–62.
[18] Fang C, Qiu S, Sun F, et al. Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. Cancer Lett 2017;410:59–62.
[19] Gong W, Tian M, Qiu H, et al. Elevated serum level of IncRNA-HIF1A-AS1 as a novel diagnostic predictor for worse prognosis in colorectal cancer. Cancer Biomark 2017;20:417–24.
[20] Ma YF, Liang T, Li GR, et al. Long non-coding RNA HNF1A-AS1 up-regulation in non-small cell lung cancer correlates to poor survival. Eur Rev Med Pharmacol Sci 2016;20:4858–63.
[21] Wu Y, Liu H, Shi X, et al. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget 2015;6:9160–72.
[22] Zhan Y, Li Y, Guan B, et al. Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. Oncotarget 2017;8:76653–63.
[23] Zhang X, Xiong Y, Tang F, et al. Long non-coding RNA HNF1A-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of the Wnt/beta-catenin signaling pathway. Biomed Pharmacother 2017;96:877–83.
[24] Zhao H, Hou W, Tao J, et al. Upregulation of IncRNA-HIF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/beta-catenin signaling pathway. Am J Transl Res 2016;8:3503–12.
[25] Lin Z, Chen W, Chen Y, et al. A new classification of lymph node metastases according to the lymph node stations for predicting prognosis in surgical patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:76261–73.
[26] Zhao LY, Yin Y, Li X, et al. A nomogram composed of clinicopathologic features and preoperative serum tumor markers to predict lymph node metastasis in early gastric cancer patients. Oncotarget 2016;7:59630–9.
[27] Mirzaei H, Gholamini S, Shahidsales S, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016;53:23–32.
[28] Fan YH, Ye MH, Wu L, et al. Overexpression of miR-98 inhibits cell invasion in glioma cell lines via downregulation of IKBepsilon. Eur Rev Med Pharmacol Sci 2015;19:3593–604.
[29] Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013;26:135–45.
[30] Zhang G, An X, Zhao H, et al. Long non-coding RNA HNF1A-AS1 promotes cell proliferation and invasion via regulating miR-17-5p in non-small cell lung cancer. Biomed Pharmacother 2017;98:594–9.